Latest news, reports, and more from the RedChip Nation.
Discovering Tomorrow's Blue Chips Today
June 24, 2021     Contact    
Featured This Week
Annovis Bio Featured in Avise Analytics Report on Most Promising Alzheimer’s Stocks


Avise Analytics, an institutional microcap research firm serving buy-side and sell-side firms, recently featured Annovis Bio (NYSE American: ANVS)as one of the five most promising Alzheimer’s stocks. Here’s an excerpt from the report:

Alzheimer’s is the sixth leading cause of death in the U.S, a disease that causes irreversible degeneration of the brain cells and affects a person’s cognitive and behavioral abilities such as impaired judgment, deteriorating memory and personality changes with the gradual loss of motor abilities and speech.

According to some compelling statistics made available by
Alzheimer’s Association over 5.8 million Americans are affected by this disorder and the numbers will most likely reach 14 million by 2050, with a new diagnosis being made every 65 seconds. The healthcare cost of Alzheimer’s and other Dementia related ailments will be over $290 billion in 2019, these numbers are likely to escalate further to over $1.1 trillion by 2050.

A report by transparency market research predicts that the global market for Alzheimer’s will reach US$6.4 billion by 2025, growing at a CAGR of 7.5%, from US$3.6 billion in 2017. The rise in ageing population, increased awareness about the benefits of combined therapy, a favorable regulatory and government support environment are some of the factors that will contribute to the growth of the market. The economic burden of the disease on not only the patients but also caregivers will act as an impediment for the market. The prohibitive cost of expensive treatment especially in developing nations is another obstacle for growth.

Alzheimer’s is one illness, where innumerable attempts have been made to find a cure with no success. According to a report released by Pharmaceutical Research and Manufacturers of America (PhRMA) from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease. However recent advancements in technology and the discovery of new molecules and combination therapies are offering renewed hope to those suffering from this illness.


Latest News
1847 Goedeker (NYSE American: GOED) Continues Strong Q2 Performance with Record Revenue Up 41.9% in May to $44.3M on a Combined Proforma Basis
Can-Fite (NYSE American: CANF) Receives Notice of Patent Allowance in China for NASH Treatment
Kiromic (NASDAQ: KRBP) Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy
Tiziana (NASDAQ: TLSA) Responds to UK Call for Development of Innovative 'Take Home' Treatments for COVID-19 Disease
Esports Entertainment Group (NASDAQ: GMBL) Launches InVIE Esports Tournament Series with Dota 2 Season 1 in South America
SPI’s (NASDAQ: SPI) Phoenix Motorcars Appoints Former Blink Charging COO as its SVP & Global Head of EV Charging Solutions
SPI’s (NASDAQ: SPI) Phoenix Motorcars Launches Full Range of EV Charging Solutions for US Market
American Resources (NASDAQ: AREC) Added to Russell Microcap Index
American Resources (NASDAQ: AREC) Further Develops Aftermarket Distribution Channels for Waste Permanent Magnets and Batteries to be Recycled for Rare Earth Elements
Vision Marine Technologies (NASDAQ: VMAR) Partners with Hellkats Powerboats and Center Console Only with the goal of Shattering the Electric Boat Top Speed World Record
DSS’s (NYSE American: DSS) Impact BioMedical Receives US Patent for its Functional Fragrance Formulation Mosquito Repellant Booster
DSS (NYSE American: DSS) Closes $50.025 Million Public Offering of Common Stock Including Exercise of the Over-Allotment
Nashville Superspeedway Selects Draganfly (OTCQB: DFLYF) Drone Services for June 18-20 NASCAR Weekend
"Remotely Flying Drones Anywhere" is Defined as the Core Business Strategy for the Enterprise Segment of Red Cat Holdings (NASDAQ: RCAT)
BTCS (OTCQB: BTCS) Grows Blockchain Infrastructure Solutions Segment with Cardano Launch
RYU Apparel (OTCQB: RYPPF) Provides Growth Strategy Update from COO Rob Blair
Alset EHome (NASDAQ: AEI) Announces Exercise and Closing of Underwriter's Over-Allotment Option
DeFi Technologies (OTC: DEFTF) Completes Acquisition of 10% of SDK:meta
DeFi Technologies' (OTC: DEFTF) Wholly Owned Subsidiary, Valour Signs LOI with Arcane Crypto with the Intention to List an Exchange-Traded Product (ETP)
CBD of Denver (OTC: CBDD) Further Expands Wholesale Business with New 300kg Monthly Production Partnership
CBD of Denver (OTC: CBDD) Expands Operations with New Sales Rep Office in Poland
Everything Blockchain (OTC: OBTX) Acquires Mercury, Inc. for $1.5M
Upcoming Zoom Webinar

Join Zoom Meeting:
One tap mobile : US: Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)

Webinar ID: 929 1864 1426
International numbers available:


Join Zoom Meeting:
Or iPhone one-tap : US: +13017158592,,86137512948#,,,,*363529#
or +13126266799,,86137512948#,,,,*363529#
Dial(for higher quality, dial a number based on your current location):
+1 646 558 8656 US (New York)
+1 301 715 8592 US (Washington D.C)
+1 312 626 6799 US (Chicago)
+1 669 900 9128 US (San Jose)
+1 253 215 8782 US (Tacoma)
+1 346 248 7799 US (Houston)
+61 7 3185 3730
or +61 8 6119 3900
or +61 8 7150 1149
or +61 2 8015 6011
or +61 3 7018 2005

Webinar ID: 861 3751 2948
Passcode: 363529
International numbers available:

Quote of the Week
"If you want to invest in the microcap space buy companies not stocks, if you buy stocks, the daily fluctuations and lack of liquidity will drive you crazy."
- Byron Roth, CEO ROTH Capital
Lesson of the Week
Learn when to sell in this week's lesson.
Read More


Latest Videos
This Week on RedChip TV: 2 Innovative Small-Cap Stocks & a Leading Fund Manager
This week’s episode of the RedChip Money Report features interviews with two innovative small-cap stocks, Elise Gaming Technology (NASDAQ: ELSI), targeting B2B and B2C gaming and sports betting opportunities with proprietary technology, and Can-Fite BioPharma (NYSE American: CANF), an advanced clinical stage biopharma with a compelling pipeline and multiple licensing agreements that could generate $140 million in milestone payments plus ongoing royalties. This week’s episode also features an exclusive interview with Christopher Krug, a leading small-cap investment manager. Visit to learn more.
Watch Now
Vision Marine: Transforming the Recreational Boating Industry with Electric Power
Vision Marine Technologies (NASDAQ: VMAR) strives to be a guiding force for change and an ongoing driving factor in fighting the problems associated with waterway pollution by disrupting the traditional boating industry with electric power, in turn directly contributing to zero pollution, zero emission and a noiseless environment.
Watch Now
Nano Dimension: Game Changing Technology with First-to-Market Advantage
Nano Dimension (Nasdaq: NNDM) is a provider of intelligent machines for the fabrication of Additively Manufactured Electronics (AME). High fidelity active electronic and electromechanical subassemblies are integral enablers of autonomous intelligent drones, cars, satellites, smartphones, and in vivo medical devices.
Watch Now
Killi: A New Paradigm in Consumer Data and Privacy
Killi (OTCQB: MYIDF) is a company driven by the evolution of consumer data and privacy. Offering compliant consumer data to brands & agencies, platforms, and data companies, Killi allows consumers to opt-in to share specific pieces of data with brands in exchange for compensation from the use of their data, democratizing data for both consumers and brands.
Watch Now
BioVie: Near-Term Catalysts from Phase 2 & Phase 3 Trials
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing transformative therapies to overcome unmet medical needs in chronic debilitating conditions. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated in a US Phase 2 study for the treatment of refractory ascites with top-line results expected in early 2022.
Watch Now
Virios Therapeutics: New Potential Treatment for Fibromyalgia
Virios Therapeutics (Nasdaq: VIRI) is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”).
Watch Now
Elys Game Technology: B2B and B2C Gaming Solutions
Elys Game Technology (Nasdaq: ELYS) is a B2B global gaming technology company operating in multiple countries worldwide, with B2C online and land-based gaming operations in Italy. In Italy, Elys offers its clients a full suite of leisure gaming products and services, such as sports betting, e-sports, virtual sports, online casino, poker, bingo, interactive games and slots.
Watch Now
Kiromic BioPharma: AI-Driven Cancer Drug Development & Gene Editing
Kiromic (NASDAQ: KRBP) is revolutionizing next-generation allogenic CAR therapies for solid tumors. The Company’s proprietary target discovery engine, Diamond uses AI and a proprietary neural network to identify development targets, dramatically compressing man years and billions of drug development dollars required to develop new live drugs.
Watch Now
RYU Apparel: Exclusive Management Interview with Award-Winning Urban Apparel Designer
RYU (OTCQB: RYPPF; TSX: RYU) is expanding its footprint globally and its new wholesale initiative with major retailers is expected to further accelerate growth in 2021 and beyond. The Company is forecasted to grow revenue at a 49% CAGR through 2024.
Watch Now
Milestone Scientific: New Innovations in Injection Technologies
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications.
Watch Now
Marpai Health: Transforming Health Plan Administration and Improving Patient Outcomes
Marpai Health is a leader in deep learning, the most advanced artificial intelligence, and brings the first SMART Health Plan Services System to self-insured companies and their employees to improve health outcomes and reduce healthcare costs. Marpai delivers a member-centric health plan administration experience powered by deep learning and SMART automation that makes it easy for members, employers and providers to improve outcomes and save money in new ways.
Watch Now
Can-Fite BioPharma: Robust Pipeline Includes 75% Enrolled Phase 3 Psoriasis Program
Can-Fite BioPharma (NYSE Amerian:CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19. The Company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis and a Phase II study in the treatment of moderate COVID-19. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH).
Watch Now
Hoth Therapeutics: Developing New Therapies for Unmet Medical Needs
Hoth Therapeutics (Nasdaq: HOTH) is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia.
Watch Now
American Resources: Raw Materials for the New Infrastructure Market
American Resources Corp. (Nasdaq: AREC) is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical rare earth minerals for the electrification market, and reprocessed metal to be recycled.
Watch Now
Genetic Technologies: Expanding Portfolio of Disease Risk Tests
Genetic Technologies (Nasdaq: GENE) is a diversified molecular diagnostics company developing tools for the prediction and assessment of cancer risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class.
Watch Now
iMetal Resources: Exploring for Gold in Eastern Canada
iMetal Resources (OTC: ADTFF) is a Canadian based junior exploration company focused on the exploration and development of its portfolio of resource properties in Ontario and Quebec. iMetal is focused on advancing its Gowganda West Project that borders Caldas Gold Corp’s 2.2 million ounce Juby Project, an advanced exploration-stage gold project located within the Shining Tree area in the southern part of the Abitibi greenstone belt about 100 km south-southeast of the Timmins gold camp.
Watch Now
Palisade Bio: Phase 2/3 Ready Drug Candidate Entering Trials 2H 2021
Palisade Bio (Nasdaq: PALI) is developing novel therapeutics designed to improve human health through therapeutic protection of the gastrointestinal (GI) mucosal barrier. PALI’s initial focus is combatting the interruption of GI function (ileus) following major surgery in order to accelerate recovery times and shorten the duration of patient hospital stays.
Watch Now
DeFi Technologies: Transforming the Global Financial System
Led by co-founders Wouter Witvoet and Olivier Roussy Newton, who collectively raised $1.4B in their prior two deals, DeFi Technologies (OTC: DEFTF) is well positioned to become a key player in the rapidly growing decentralized finance industry. The market size for the industry is measured in the trillions and spans multiple sectors, including insurance, derivatives, credit and lending, asset management, and exchanges.
Watch Now
Amesite: AI-Driven EdTech Transforming Learning
Amesite (Nasdaq: AMST) is an ed-tech, SaaS company with the most advanced artificial intelligence driven online learning platform in the industry, providing both content creation and a best-in-class infrastructure for the multi-billion-dollar online learning markets in business and education. The Company leverages existing institutional infrastructures, adding mass customization and cutting-edge technology to provide cost-effective, scalable, and engaging experiences for learners anywhere.
Watch Now
CBD of Denver Interviewed on Benzinga’s Cannabis Insider
CBD of Denver (CBDD) is a full-line CBD and hemp oil company, producing and distributing cannabis and CBD products in Switzerland, Europe, and the US. CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for its shareholders and is driven by a passion to improve lives and strengthen communities by unleashing the full potential of cannabis.
Watch Now
Tiziana Life Sciences: Robust Pipeline with Multiple Near-Term Catalysts
Tiziana Life Sciences (NASDAQ: TLSA) has developed proprietary oral, nasal, and inhaled formulation technologies that could transform immunotherapies with Monoclonal Antibodies currently administered intravenously for multiple indications.
Watch Now
Medalist Diversified REIT: Targeting Attractive Opportunities in Secondary Markets in Southeast U.S.
Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions.
Watch Now Transforming the World of Recruiting (OTCQB: RCRT) is a hiring platform for the world’s largest network of recruiters. empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The network of over 28,000 small and independent recruiters utilize an innovative web platform, complete with AI-driven job matching, screening and video interviewing to recruit talent faster.
Watch Now
Aptorum Group: Developing Novel Therapeutics for Unmet Medical Needs
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum's current drug pipeline includes indications in orphan diseases, infectious diseases, and metabolic diseases.
Watch Now
EVmo: Leading Provider of Rental Vehicles for the Gig Economy
EVmo (OTC: YAYO) bridges the gap between rideshare drivers in need of a suitable vehicle and rideshare companies that depend on attracting and keeping drivers. EVmo uniquely supports drivers in both the higher and lower economic categories with innovative policies and programs. EVmo is a leading provider of rental vehicles to drivers in the ever-expanding gig economy.
Watch Now
Order Small Stocks, Big Money Today!
Dave Gentry is the author of Small Stocks, Big Money: Interviews With Microcap Superstars. Published by Wiley, this first-hand perspective on the fast world of microcap investing is now available for purchase.
MidSouth Week in Review
US small-cap value stocks returned 76.8% in the half year ending March 31 vs. 14.4% for large cap growth companies.
Read More
About RedChip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Disclosure
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at and view RedChip’s Disclosures.
Copyright © 2021 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.